Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today issued a letter to stockholders recommending that stockholders vote ‘FOR’ Proposals No. 2 and No. 3 of Advaxis’ definitive proxy statement on Schedule 14A as filed with the U.S. Securities and Exchange Commission on April 30, 2013, and as supplemented to date. The letter conveys compelling reasons why Advaxis believes that approval of these proposals is the best strategic move for, and in the best interests of, its stockholders.
Help employers find you! Check out all the jobs and post your resume.
